WO2023107082A1 - Comprimé pelliculé de saxagliptine et d'au moins un antioxydant traité par granulation humide - Google Patents

Comprimé pelliculé de saxagliptine et d'au moins un antioxydant traité par granulation humide Download PDF

Info

Publication number
WO2023107082A1
WO2023107082A1 PCT/TR2022/051467 TR2022051467W WO2023107082A1 WO 2023107082 A1 WO2023107082 A1 WO 2023107082A1 TR 2022051467 W TR2022051467 W TR 2022051467W WO 2023107082 A1 WO2023107082 A1 WO 2023107082A1
Authority
WO
WIPO (PCT)
Prior art keywords
film coated
coated tablet
saxagliptin
antioxidant
tablet according
Prior art date
Application number
PCT/TR2022/051467
Other languages
English (en)
Inventor
Nur PEHLIVAN AKALIN
Aydan OZDEN
Gulcan ARSIN
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2021/019469 external-priority patent/TR2021019469A1/tr
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2023107082A1 publication Critical patent/WO2023107082A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Definitions

  • the present invention relates to a film coated tablet comprising a granulate comprising saxagliptin or a pharmaceutically acceptable salt thereof or crystalline polymorph thereof and at least one antioxidant, wherein the granulate is obtained by wet-granulation using ethanol.
  • DPP-IV dipeptidyl peptidase IV
  • GLP-1 glucagon like peptide-1
  • DPP-IV inhibitors also commonly known as gliptins, competitively inhibit the enzyme DPP-IV, thereby increasing the endogenous concentration of GLP-1 , which further augments insulin secretion and improves the glycemic profile of patients with diabetes.
  • Saxagliptin is a dipeptidyl peptidase IV (DPP-IV) inhibitor used for the treatment of type 2 diabetes mellitus.
  • DPP-IV dipeptidyl peptidase IV
  • U.S. Patent No. 6,395,767 discloses the compound saxagliptin.
  • saxagliptin is an unstable compound and it can undergo a thermodynamically favored cyclization to form the corresponding cyclic amidine. This cyclization reaction can occur both in solid state and solution state. The challenge of minimizing or preventing the cyclization reaction during manufacture of saxagliptin formulations is particularly significant. Also, saxagliptin or a pharmaceutically acceptable salt thereof or crystalline polymorph thereof is used small proportion that can lead to considerable problems during the manufacture of the composition with regard to the uniformity of the content of active agent in the individual composition units.
  • US 6,395,767 discloses a DPP4 inhibiting compound, saxagliptin and its use in treating type- 11 diabetes mellitus.
  • WO 2011/052825 discloses a composition of DPP4 inhibitors and anti-diabetic compounds for use in the treatment of diabetes.
  • US 7,951 ,400 discloses a coated tablet formulation of saxagliptin containing a polyvinyl alcohol based coating.
  • the present invention discloses a film coated tablet comprising a granulate comprising saxagliptin or a pharmaceutically acceptable salt thereof or crystalline polymorph thereof and at least one antioxidant, wherein the granulate is obtained by wet-granulation using ethanol.
  • the film coated tablet is created to overcome the above problems and provides additional advantages to the relevant field of art. Other advantages and embodiments of the present invention will be clarified in the following description.
  • the present invention relates to a film coated tablet comprising a granulate comprising saxagliptin or a pharmaceutically acceptable salt thereof or crystalline polymorph thereof and at least one antioxidant, wherein the granulate is obtained by wet-granulation using ethanol. So, this way eliminates the problems stability of active agent and provides additional advantages to the relevant field of art. Based on the state of the art, the main object of the present invention is to obtain stable a tablet with improved stability and content uniformity and compressibility, flowability by wet granulation.
  • Saxagliptin or a pharmaceutically acceptable salt thereof or crystalline polymorph thereof is used small proportion that can lead to considerable problems during the manufacture of the composition with regard to the uniformity of the content of active agent in the individual composition units.
  • wet granulation is preferred in terms of pharmacotechnical properties, such as flowability, compressibility and content uniformity of saxagliptin.
  • using ethanol also provides the desired stability.
  • a film coated tablet comprises a granulate comprising saxagliptin or a pharmaceutically acceptable salt thereof or crystalline polymorph thereof and at least one antioxidant, wherein the granulate is obtained by wetgranulation using ethanol.
  • wet granulation process is effective to solve the flowability problems associated with dry granulation, there can be problems with binding when the process is scaled up to an industrial scale. It has been found that these problems can be solved by using a wet granulation process using ethanol granulation liquid as in which part of the antioxidant is mixed with the saxagliptin, for example in a powder form, and the remaining part is present in the granulation liquid.
  • the weight ratio of antioxidant to saxagliptin or a pharmaceutically acceptable salt thereof or crystalline polymorph thereof is between 2.0 and 10.0, preferably is between 4.0 and 8.0.
  • the weight ratio of antioxidant to saxagliptin or a pharmaceutically acceptable salt thereof or crystalline polymorph thereof is between 5.0 and 6.5.
  • Suitable antioxidants are selected from the group comprising ascorbic acid, sodium ascorbate, ascorbyl palmitate, erythorbic acid, butylated hydroxy anisole, butylated hydroxy toluene, propyl gallate, sodium sulfite, sodium metabisulfite, sodium bisulfite, thioglycollic acid, alpha tocopherol, tocopherol, thioglycerols, thiogallic acid, cysteine, glutathione, cysteamine, dihydrolipoic acid, lipoic acid, thioredoxin, propyl gallate, ethyl gallate, methyl gallate, lauryl gallate or mixtures thereof.
  • the antioxidant is alpha tocopherol, ascorbic acid, sodium ascorbate, ascorbyl palmitate, erythorbic acid, propyl gallate, ethyl gallate, methyl gallate, lauryl gallate or mixtures thereof.
  • the antioxidant is gallates, for example; propyl gallate, ethyl gallate, methyl gallate, lauryl gallate.
  • the antioxidant is ascorbic acid.
  • the antioxidant is alpha tocopherol.
  • the antioxidant is sodium ascorbate.
  • the antioxidant is ascorbyl palmitate.
  • the antioxidant is erythorbic acid.
  • Too little or too much antioxidant can affect the stability of the tablet of saxagliptin or a pharmaceutically acceptable salt thereof or crystalline polymorph thereof and an appropriate amount of antioxidant must therefore be present in this tablet.
  • the amount of antioxidant is between 0.2% and 4.0% by weight in the total film coated tablet.
  • the amount of antioxidant is between 0.5% and 2.50% by weight in the total film coated tablet.
  • the amount of saxagliptin or a pharmaceutically acceptable salt thereof or crystalline polymorph thereof is between 1.0% and 15.0% by weight in the total film coated tablet. Preferably, it is between 3.0% and 10.0% by weight in the total film coated tablet.
  • saxagliptin or a pharmaceutically acceptable salt thereof or crystalline polymorph thereof is present as saxagliptin hydrochloride dihydrate.
  • the use of this form of saxagliptin helps to achieve the desired stability.
  • the amount of saxagliptin hydrochloride dihydrate is between 1.0% and 15.0% by weight in the total film coated tablet. Preferably, it is between 3.0% and 10.0% by weight in the total film coated tablet.
  • excipients provided in a composition may positively or negatively influence the physicochemical and pharmacokinetic properties, e.g. the solubility, stability, absorption, bioavailability of an active agent. For this reason, the excipients which accompany an active agent have to be selected in a careful and conscious manner while a composition is developed because saxagliptin or a pharmaceutically acceptable salt thereof or crystalline polymorph thereof is a low dose drug and hence the ratio of excipients to drug is high.
  • the composition should have no physicochemical incompatibility between the active agents and the excipients. If active agent is incompatible of excipients, stability and psychochemical problems may be during or after the process.
  • the tablet comprises at least one pharmaceutically acceptable excipient selected from the group comprising fillers, disintegrants or mixtures thereof.
  • Suitable disintegrants are selected from the group comprising mannitol, starch, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, hydroxymethyl starch or mixtures thereof.
  • the disintegrant is mannitol.
  • Suitable fillers are selected from group comprising talc, lactose anhydrous, microcrystalline cellulose, dicalcium phosphate dihydrate, ammonium alginate, calcium carbonate, calcium phosphate, calcium sulfate, cellulose, cellulose acetate, dextrates, dextrin, dextrose, erythritol, ethylcellulose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, polydextrose, polymethacrylates, sodium alginate, sodium chloride, starch, sugar spheres, sulfobutylether beta-cyclodextrin, polysorbate 80, xylitol or mixtures thereof.
  • the filler is talc or lactose anhydrous or mixtures thereof.
  • both talc and lactose anhydrous are used. It’s important to choose diluent and use the diluent in a specific amount for providing a good uniformity of content and avoiding stability problems. Since the tablet has porous characteristics, it’s sensitive to humidity and fragility which may be lead to stability problems. Furthermore, this stability problem becomes a big challenge due to cyclization reaction problem of saxagliptin.
  • the tablet further comprises at least one lubricant.
  • Suitable lubricants are selected from the group comprising stearic acid, sodium stearyl fumarate, magnesium stearate, sodium lauryl sulphate, zinc stearate, calcium stearate, mineral oil, talc, polyethylene glycol, glyceryl monostearate, glyceryl palmitostearate, magnesium lauryl sulphate, fumaric acid, zinc stearate or mixtures thereof.
  • the lubricant is stearic acid. Using the described lubricant helps to provide the desired flowability and compressibility.
  • the obtained tablet by wet granulation comprises;
  • the obtained tablet by wet granulation comprises;
  • a method for preparing a film coated tablet comprises the following steps: a) Mixing saxagliptin HCI Dihydrate, at least one filler and at least one antioxidant, b) Granulating the mixture with ethanol, c) Adding at least one disintegrant and at least one filler and then mixing, d) Adding at least one lubricant and then mixing, e) Compressing to form of tablets, f) Coating tablets with film coating.
  • a method for preparing a film coated tablet comprises the following steps: a) Mixing saxagliptin HCI Dihydrate, the half of lactose anhydrate and at least one antioxidant, b) Granulating the mixture with ethanol, c) Adding the remaining part of lactose anhydrate, mannitol and talc and then mixing, d) Adding stearic acid and then mixing, e) Compressing to form of tablets, f) Coating tablets with film coating.
  • a process for example 1 a) Mixing saxagliptin HCI Dihydrate, at least one filler and at least one antioxidant, b) Granulating the mixture with ethanol, c) Adding at least one disintegrant and at least one filler and then mixing, d) Adding at least one lubricant and then mixing, e) Compressing to form of tablets, f) Coating tablets with film coating.
  • Example 2 q.s.: sufficient quantity
  • Example 3 q.s.: sufficient quantity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un comprimé pelliculé comprenant un granulat contenant de la saxagliptine ou un sel pharmaceutiquement acceptable de celle-ci ou un polymorphe cristallin de celle-ci et au moins un antioxydant, le granulat étant obtenu par granulation humide à l'aide d'éthanol.
PCT/TR2022/051467 2021-12-09 2022-12-09 Comprimé pelliculé de saxagliptine et d'au moins un antioxydant traité par granulation humide WO2023107082A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2021/019469 TR2021019469A1 (tr) 2021-12-09 A film coated tablet of saxagliptin and at least one antioxidant processed with wet granulation
TR2021019469 2021-12-09

Publications (1)

Publication Number Publication Date
WO2023107082A1 true WO2023107082A1 (fr) 2023-06-15

Family

ID=86730948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2022/051467 WO2023107082A1 (fr) 2021-12-09 2022-12-09 Comprimé pelliculé de saxagliptine et d'au moins un antioxydant traité par granulation humide

Country Status (1)

Country Link
WO (1) WO2023107082A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102086172A (zh) * 2011-01-13 2011-06-08 廖国超 沙格列汀的药用盐及其制备方法
CN102379869A (zh) * 2010-08-31 2012-03-21 林飞 包含沙格列汀的口服制剂及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102379869A (zh) * 2010-08-31 2012-03-21 林飞 包含沙格列汀的口服制剂及其应用
CN102086172A (zh) * 2011-01-13 2011-06-08 廖国超 沙格列汀的药用盐及其制备方法

Similar Documents

Publication Publication Date Title
US20090324718A1 (en) Imatinib compositions
WO2021086292A1 (fr) Formulations de comprimés bicouches comprenant de la dapagliflozine et de la metformine
JP2007056011A (ja) 小型化塩酸サルポグレラート経口投与製剤
EP1965773B1 (fr) Formulation orale de forme i d'olanzapine anhydre
WO2023107082A1 (fr) Comprimé pelliculé de saxagliptine et d'au moins un antioxydant traité par granulation humide
EP4025194A1 (fr) Combinaison comprenant de la vildagliptine et de la metformine
EP4285894A1 (fr) Formulation d'empagliflozine et de chlorhydrate de metformine
WO2022119541A1 (fr) Formulation de comprimé pelliculé comprenant de la dapagliflozine et du chlorhydrate de metformine
EP1950205A1 (fr) Procede de stabilisation d'un compose d'isoxazole
TR2021019469A1 (tr) A film coated tablet of saxagliptin and at least one antioxidant processed with wet granulation
TR2021016647A2 (tr) Saksagli̇pti̇n ve en az bi̇r anti̇oksi̇dan i̇çeren di̇rekt baskiyla hazirlanmiş kati farmasöti̇k kompozi̇syonlar
TR2021016644A2 (tr) Saksagli̇pti̇n ve en az bi̇r anti̇oksi̇dan i̇çeren bi̇r fi̇lm kapli tablet
WO2022119540A2 (fr) Procédé pour formulations de dapagliflozine et de chlorhydrate de metformine
AU2021390901B2 (en) Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
EP4162929A1 (fr) Formulation composite comprenant de la sitagliptine et de la dapagliflozine, et son procédé de préparation
JP7355846B2 (ja) 固形製剤
EP4282415A1 (fr) Composition de comprimé stable d'axitinib
US20060051410A1 (en) Pharmaceutical composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid
EP4079296A1 (fr) Formulation de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
WO2023234901A1 (fr) Formulation comprenant de l'empagliflozine et du chlorhydrate de metformine
EP4212150A1 (fr) Composition de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
WO2024162930A1 (fr) Comprimés pelliculés d'empagliflozine et de chlorhydrate de metformine
WO2023136797A2 (fr) Composition de comprimé bicouche comprenant de la metformine et de la dapagliflozine amorphe
EP4410280A1 (fr) Comprimés d'enrobage de film d'empagliflozine et de chlorhydrate de metformine
WO2023234900A1 (fr) Comprimé comprenant de l'empagliflozine et du chlorhydrate de metformine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22904845

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE